Glenwood Goss

Glenwood Goss

UNVERIFIED PROFILE

Are you Glenwood Goss?   Register this Author

Register author
Glenwood Goss

Glenwood Goss

Publications by authors named "Glenwood Goss"

Are you Glenwood Goss?   Register this Author

83Publications

2836Reads

45Profile Views

Inpatients versus outpatients with advanced non-small cell lung cancer: Characteristics and outcomes.

Cancer Treat Res Commun 2019 23;19:100130. Epub 2019 Mar 23.

Department of Medicine, University of Ottawa, 501 Smyth Road, Ottawa, Ontario K1H 8L6, Canada; Ottawa Hospital Cancer Centre, Ottawa, 501 Smyth Road, Ottawa, Ontario K1H 8L6, Canada; Ottawa Hospital Research Institute, 725 Parkdale Avenue, Ottawa, Ontario K1Y4E9, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctarc.2019.100130DOI Listing
September 2019

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.

N Engl J Med 2019 02 4;380(8):711-719. Epub 2018 Dec 4.

From the Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa (M.C., R.M., G.G., G.L.G., D.S., T.R., M.R., D.W., P.S.W.), Centre Intégré de Santé et des Services Sociaux de l'Outaouais, Gatineau, QC (K.A.-N.), Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Montreal (V.T.), Nova Scotia Health Authority, Halifax (S. Shivakumar), Lakeridge Health, Oshawa, ON (A.S.), William Osler Health Centre, Brampton, ON (P.K.), Sault Area Hospital, Sault Ste. Marie, ON (D.H., S. Spadafora), Hôpital Régional de Rimouski, Rimouski, QC (K.M.), Markham Stouffville Hospital, Markham, ON (M.T.), Kingston General Hospital, Kingston, ON (A.T.), University of British Columbia, British Columbia Cancer Agency, Vancouver (A.Y.Y.L.), Hamilton Health Sciences, Hamilton, ON (P.L.G.), London Health Sciences Centre, London, ON (A.L.-L.), and Royal Victoria Regional Health Centre, Barrie, ON (R.E.-M.) - all in Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1814468DOI Listing
February 2019

Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe.

Clin Lung Cancer 2017 01 27;18(1):5-12. Epub 2016 Jun 27.

Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2016.06.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361177PMC
January 2017

Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not.

Lung Cancer 2016 07 14;97:15-21. Epub 2016 Apr 14.

Department of Medicine, University of Ottawa, Ottawa, ON, Canada; Ottawa Hospital Research Institute, Ottawa, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2016.04.007DOI Listing
July 2016

Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.

Oncologist 2016 Feb 14;21(2):205-13. Epub 2016 Jan 14.

Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0209DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746081PMC
February 2016

miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma.

Clin Lung Cancer 2015 Nov 3;16(6):e121-9. Epub 2015 Feb 3.

Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Department of Biochemistry, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2015.01.008DOI Listing
November 2015

Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial.

Lung Cancer 2015 Nov 16;90(2):288-95. Epub 2015 Sep 16.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network, and the University of Toronto, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.09.004DOI Listing
November 2015

Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer.

Curr Opin Oncol 2015 Mar;27(2):102-7

aOttawa Hospital Research Institute bOttawa Hospital Cancer Centre cDepartment of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000163DOI Listing
March 2015

Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada.

J Thorac Oncol 2014 Oct;9(10):1449-58

*The Canadian Centre for Applied Research in Cancer Control, and the British Columbia Cancer Agency, Vancouver, British Columbia, Canada; †The British Columbia Cancer Agency, Vancouver, British Columbia, Canada; ‡Brock University, St. Catherines, Ontario, Canada; §Cancer Care Ontario and the Juravinski Cancer Centre, Hamilton, Ontario, Canada; ‖University Health Network and Princess Margaret Cancer Centre, Toronto, Ontario, Canada; ¶The Canadian Centre for Applied Research in Cancer Control, the British Columbia Cancer Agency and School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada; #The University of British Columbia School of Population and Public Health, Vancouver, British Columbia, Canada; **Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada; ††The British Columbia Cancer Agency and The Canadian Centre for Applied Research in Cancer Control and the University of British Columbia, Vancouver, British Columbia, Canada; ‡‡Beatrice Hunter Cancer Research Institute and Dalhousie University, Halifax, Nova Scotia, Canada; §§The Vancouver General Hospital, Vancouver, British Columbia, Canada; ‖‖Fionna Stanley Hospital and Sir Charles Gairdner Hospital, Perth, Western Australia; ¶¶Université Laval, Québec, Canada; ##Vancouver General Hospital, The University of British Columbia, Vancouver, British Columbia, Canada; ***The Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada; †††Princess Margaret Cancer Centre, Toronto, Ontario, Canada; ‡‡‡University of Calgary, Foothills Medical Centre, Calgary, Alberta, Canada; §§§Foothills Medical Centre, Calgary, Alberta, Canada; ‖‖‖Memorial University, St. Johns, Newfoundland, Canada; ¶¶¶The Ottawa Hospital, Ottawa, Ontario, Canada; ###Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; ****The Vancouver General Hospital and The University of British Columbia, Vancouver, British

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000283DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165479PMC
October 2014

Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and Future.

Front Oncol 2014 27;4:233. Epub 2014 Aug 27.

Ottawa Hospital Research Institute , Ottawa, ON , Canada ; Ottawa Hospital Cancer Centre , Ottawa, ON , Canada ; Department of Medicine, University of Ottawa , Ottawa, ON , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2014.00233DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145253PMC
September 2014

Phase II study of accelerated hypofractionated three-dimensional conformal radiotherapy for stage T1-3 N0 M0 non-small cell lung cancer: NCIC CTG BR.25.

J Natl Cancer Inst 2014 Aug 29;106(8). Epub 2014 Jul 29.

Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada (PC, YCU); Montreal General Hospital, McGill University, Montreal, Quebec, Canada (SF); CancerCare Manitoba, Winnipeg, Manitoba, Canada (SA); Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada (PC); Dr. H. Bliss Murphy Cancer Centre, St John's, Newfoundland, Canada (JG); Tom Baker Cancer Centre, Calgary, Alberta, Canada (EK); BC Cancer Agency-Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada (IM); Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada (JRW); QEII Centre for Clinical Research Trials, Halifax, Nova Scotia, Canada (HH); Cancer Centre of Southeastern Ontario, Queen's University, Kingston, Ontario, Canada (CdM); Atlantic Health Sciences Corporation, Saint John Regional Hospital, Saint John, New Brunswick, Canada (HC); CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada (TTV); BC Cancer Agency-Fraser Valley Centre, Surrey, British Columbia, Canada (AK); BC Cancer Agency-Vancouver Island Cancer Centre, Victoria, British Columbia, Canada (ESW); Ottawa Health Research Institute-General Division, Ottawa, Ontario, Canada (GG); University Health Network-OCI/Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada (FAS); NCIC Clinical Trials Group, Queen's University, Kingston, Ontario, Canada (PO, KD, CO).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju164DOI Listing
August 2014

Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer.

Front Oncol 2014 23;4:190. Epub 2014 Jul 23.

Ottawa Hospital Research Institute , Ottawa, ON , Canada ; Ottawa Hospital Cancer Centre , Ottawa, ON , Canada ; Department of Medicine, University of Ottawa , Ottawa, ON , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2014.00190DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107955PMC
August 2014

NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer.

J Thorac Oncol 2014 Mar;9(3):410-3

*Department of Oncology, McMaster University, Juravinski Cancer Centre, Hamilton Ontario, Canada; †Medical Oncology Department, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; ‡Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada; and §NCIC CTG Queens University, Kingston, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000058DOI Listing
March 2014

Reply to F. Gelsomino et al.

J Clin Oncol 2013 Sep 12;31(26):3293-4. Epub 2013 Aug 12.

The Ottawa Hospital Cancer Centre, the University of Ottawa, Ottawa, Ontario, Canada.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2013.50.8705
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.50.8705DOI Listing
September 2013

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.

J Clin Oncol 2013 Sep 26;31(27):3320-6. Epub 2013 Aug 26.

Glenwood D. Goss and Ian Lorimer, Ottawa Hospital Cancer Center, University of Ottawa, Ottawa; Chris O'Callaghan and Keyue Ding, NCIC CTG, Queens University, Kingston; Ming-Sound Tsao and Frances A. Shepherd, University Health Network, Princess Margaret Hospital, University of Toronto, Toronto; Jonathan Noble, Northeast Cancer Center, Sudbury, Ontario; Charles Butts, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada; Gregory A. Masters, Christiana Care's Helen F. Graham Cancer Center, Newark, DE; James Jett, National Jewish Health, Division of Oncology, Denver, CO; Martin J. Edelman, Greenebaum Cancer Center, University of Maryland, Baltimore, MD; Rogerio Lilenbaum, Smilow Cancer Hospital, Yale Cancer Center, New Haven, CT; Hak Choy, Kemp Kernstine, and Joan Schiller, The University of Texas, Southwestern Medical Center, Dallas; Katherine Pisters, The University of Texas MD Anderson Cancer Center, Houston, TX; Fadlo Khuri, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA; David Gandara, University of California, Davis Cancer Center, Sacramento, CA; Thomas A. Hensing, NorthShore University Health System, The University of Chicago, Chicago; and Kendrith Rowland, Carle Cancer Center, Urbana, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.51.1816DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3770864PMC
September 2013

Non-small-cell lung cancer: then and now.

J Clin Oncol 2013 Mar 11;31(8):981-3. Epub 2013 Feb 11.

Division of Hematology-Oncology, University of Texas Southwestern, Dallas, TX 75390-8852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.47.5772DOI Listing
March 2013

Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer.

J Clin Oncol 2013 Mar 11;31(8):1061-9. Epub 2013 Feb 11.

Division of Medical Oncology, Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/31/8/1061.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2012.43.4522
Publisher Site
http://dx.doi.org/10.1200/JCO.2012.43.4522DOI Listing
March 2013

Tumor vasculature as a therapeutic target in non-small cell lung cancer.

J Thorac Oncol 2012 Mar;7(3):609-20

Division of Medical Oncology, The Ottawa Hospital Cancer Centre, University of Ottawa, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182435f3eDOI Listing
March 2012

Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21.

J Clin Oncol 2010 Dec 15;28(36):5247-56. Epub 2010 Nov 15.

Cancer Therapeutics Program, Ottawa Hospital Research Institute, Box 926, 3rd Floor TOHRCC, 501 Smyth Rd, Ottawa, Ontario, Canada K1H 8L6.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2010.31.0805
Publisher Site
http://dx.doi.org/10.1200/JCO.2010.31.0805DOI Listing
December 2010

The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer.

Int J Cancer 2009 Feb;124(4):806-15

Division of Gynaecologic Oncology, The Ottawa Hospital, Ottawa, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.23987DOI Listing
February 2009

Nomograms to predict serious adverse events in phase II clinical trials of molecularly targeted agents.

J Clin Oncol 2008 Mar;26(8):1324-30

Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, 610 University Ave, Ste 5-718, Toronto, Ontario, M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.14.0673DOI Listing
March 2008

Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway.

Clin Cancer Res 2006 Jul;12(14 Pt 2):4426s-4431s

Centre for Cancer Therapeutics, Ottawa Hospital Regional Cancer Centre and Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-0089DOI Listing
July 2006

Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.

Clin Cancer Res 2005 Mar;11(6):2398-407

Centre for Cancer Therapeutics and Medical Oncology, Ottawa Regional Cancer Centre, Ottawa Health Research Institute, 503 Smyth Road, Ottawa, Ontario, Canada K1H 1C4.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-04-1951DOI Listing
March 2005

Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells.

J Cancer Res Clin Oncol 2003 Nov 26;129(11):631-41. Epub 2003 Aug 26.

Centre for Cancer Therapeutics, Ottawa Regional Cancer Centre, 503 Smyth Road, Third Floor, Ottawa, Ontario, K1H 1C4, Canada.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00432-003-0490-2
Publisher Site
http://dx.doi.org/10.1007/s00432-003-0490-2DOI Listing
November 2003